 Biosimilar Pharmaceuticals
"Biosimilar Pharmaceuticals" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
BIOLOGIC PRODUCTS that are imitations but not exact replicas of innovator products.
| Descriptor ID |
D059451
|
| MeSH Number(s) |
D20.215.261
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Biosimilar Pharmaceuticals".
Below are MeSH descriptors whose meaning is more specific than "Biosimilar Pharmaceuticals".
This graph shows the total number of publications written about "Biosimilar Pharmaceuticals" by people in this website by year, and whether "Biosimilar Pharmaceuticals" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 3 | 1 | 4 | | 2018 | 5 | 0 | 5 | | 2019 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Biosimilar Pharmaceuticals" by people in Profiles.
-
Dwadasi S, Israel A, Rubin DT. The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know? Gastrointest Endosc Clin N Am. 2019 Jul; 29(3):405-419.
-
Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019 Apr; 80(4):1029-1072.
-
Parsad S, Nabhan C. Biosimilars. JAMA Oncol. 2018 07 01; 4(7):1023.
-
Lyman GH, Zon R, Harvey RD, Schilsky RL. Reply to S.D. Lucio. J Clin Oncol. 2018 07 10; 36(20):2127.
-
Lyman GH, Zon R, Harvey RD, Schilsky RL. Rationale, Opportunities, and Reality of Biosimilar Medications. N Engl J Med. 2018 May 24; 378(21):2036-2044.
-
Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, Zon R, Francisco M, Green S, Sherwood S, Harvey RD, Schilsky RL. American Society of Clinical Oncology Statement: Biosimilars in Oncology. J Clin Oncol. 2018 04 20; 36(12):1260-1265.
-
Nabhan C, Parsad S, Mato AR, Feinberg BA. Biosimilars in Oncology in the United States: A Review. JAMA Oncol. 2018 Feb 01; 4(2):241-247.
-
Komaki Y, Yamada A, Komaki F, Sakuraba A. Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients-authors' reply. Aliment Pharmacol Ther. 2017 11; 46(9):905-906.
-
Komaki Y, Yamada A, Komaki F, Micic D, Ido A, Sakuraba A. Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply. Aliment Pharmacol Ther. 2017 05; 45(10):1372.
-
Komaki Y, Yamada A, Komaki F, Micic D, Ido A, Sakuraba A. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-a agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017 04; 45(8):1043-1057.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|